BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Grabowski GA, Antommaria AHM, Kolodny EH, Mistry PK. Gaucher disease: Basic and translational science needs for more complete therapy and management. Mol Genet Metab 2021;132:59-75. [PMID: 33419694 DOI: 10.1016/j.ymgme.2020.12.291] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Ivanova MM, Dao J, Kasaci N, Friedman A, Noll L, Goker-alpan O. Wnt signaling pathway inhibitors, sclerostin and DKK-1, correlate with pain and bone pathology in patients with Gaucher disease. Front Endocrinol 2022;13. [DOI: 10.3389/fendo.2022.1029130] [Reference Citation Analysis]
2 Giraldo P, Andrade‐campos M, Morales M, the Sega (SEguimiento del paciente de Gaucher, Gaucher patie. Recommendations on the follow‐up of patients with Gaucher disease in Spain: Results from a Delphi survey. JIMD Reports 2022. [DOI: 10.1002/jmd2.12342] [Reference Citation Analysis]
3 Feldman RA. Microglia orchestrate neuroinflammation. Elife 2022;11:e81890. [PMID: 35993545 DOI: 10.7554/eLife.81890] [Reference Citation Analysis]
4 Boddupalli CS, Nair S, Belinsky G, Gans J, Teeple E, Nguyen TH, Mehta S, Guo L, Kramer ML, Ruan J, Wang H, Davison M, Kumar D, Vidyadhara DJ, Zhang B, Klinger K, Mistry PK. Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells, biomarkers, and response to substrate reduction therapy. Elife 2022;11:e79830. [PMID: 35972072 DOI: 10.7554/eLife.79830] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Grabowski GA, Mistry PK. Therapies for lysosomal storage diseases: Principles, practice, and prospects for refinements based on evolving science. Molecular Genetics and Metabolism 2022. [DOI: 10.1016/j.ymgme.2022.07.014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Boddupalli CS, Nair S, Belinsky G, Gans J, Teeple E, Nguyen T, Mehta S, Guo L, Kramer ML, Ruan J, Wang H, Davison M, Vidyadhara D, Bailin Z, Klinger K, Mistry PK. Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells.. [DOI: 10.1101/2022.05.13.491834] [Reference Citation Analysis]
7 Niederau C. Lysosomale Speicherkrankheiten. Gastro-News 2022;9:36-37. [DOI: 10.1007/s15036-022-2470-x] [Reference Citation Analysis]
8 Weinreb NJ, Goker-alpan O, Kishnani PS, Longo N, Burrow TA, Bernat JA, Gupta P, Henderson N, Pedro H, Prada CE, Vats D, Pathak RR, Wright E, Ficicioglu C. The diagnosis and management of Gaucher disease in pediatric patients: Where do we go from here? Molecular Genetics and Metabolism 2022. [DOI: 10.1016/j.ymgme.2022.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Roh J, Subramanian S, Weinreb NJ, Kartha RV. Gaucher disease – more than just a rare lipid storage disease. J Mol Med. [DOI: 10.1007/s00109-021-02174-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kishnani PS, Al-Hertani W, Balwani M, Göker-Alpan Ö, Lau HA, Wasserstein M, Weinreb NJ, Grabowski G. Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: Results from a Delphi consensus. Mol Genet Metab 2021:S1096-7192(21)01194-X. [PMID: 34972655 DOI: 10.1016/j.ymgme.2021.12.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Magnusen AF, Rani R, McKay MA, Hatton SL, Nyamajenjere TC, Magnusen DNA, Köhl J, Grabowski GA, Pandey MK. C-X-C Motif Chemokine Ligand 9 and Its CXCR3 Receptor Are the Salt and Pepper for T Cells Trafficking in a Mouse Model of Gaucher Disease. Int J Mol Sci 2021;22:12712. [PMID: 34884512 DOI: 10.3390/ijms222312712] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Daykin E, Fleischer N, Abdelwahab M, Hassib N, Schiffmann R, Ryan E, Sidransky E. Investigation of a dysmorphic facial phenotype in patients with Gaucher disease types 2 and 3. Mol Genet Metab 2021;134:274-80. [PMID: 34663554 DOI: 10.1016/j.ymgme.2021.09.008] [Reference Citation Analysis]
13 Kleytman N, Ruan J, Ruan A, Zhang B, Murugesan V, Lin H, Guo L, Klinger K, Mistry PK. Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease. Mol Genet Metab Rep 2021;29:100798. [PMID: 34485083 DOI: 10.1016/j.ymgmr.2021.100798] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Peng Y, Liou B, Lin Y, Fannin V, Zhang W, Feldman RA, Setchell KDR, Grabowski GA, Sun Y. Substrate Reduction Therapy Reverses Mitochondrial, mTOR, and Autophagy Alterations in a Cell Model of Gaucher Disease. Cells 2021;10:2286. [PMID: 34571934 DOI: 10.3390/cells10092286] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
15 Narayanan P, Nair S, Balwani M, Malinis M, Mistry P. The clinical spectrum of SARS-CoV-2 infection in Gaucher disease: Effect of both a pandemic and a rare disease that disrupts the immune system. Mol Genet Metab 2021:S1096-7192(21)00768-X. [PMID: 34412940 DOI: 10.1016/j.ymgme.2021.08.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]